CJC-1295 Prescription: How to Get One

The short answer

You can ask a licensed US provider for a CJC-1295 prescription, and some will write one after an evaluation. The harder part is the pharmacy. CJC-1295 is not an FDA-approved drug, and in mid-2026 it sits in a specific regulatory gap: it was removed from the FDA’s restricted compounding list earlier this year, but it has not been formally added to the permitted list. Until that’s resolved, a compounding pharmacy has no clean legal basis to fill the script.

So the realistic situation in June 2026 is: a prescription is necessary, but a prescription alone may not get you a lawfully compounded product. This page explains who can prescribe, how telehealth fits in, what an honest evaluation looks like, and why CJC-1295 specifically is a more complicated request than many of the peptides it’s usually grouped with.

Note: This is educational information about how the prescribing process works, not medical advice and not a dosing guide. CJC-1295’s legal status is described as current to the date at the top of this page and is actively changing through 2026.

Why a CJC-1295 prescription is different in 2026

For an FDA-approved medication, a prescription is straightforward: a licensed provider writes it, any pharmacy fills it. CJC-1295 has never cleared that bar. There is no approved label, no agency-approved indication, and no finished pharmaceutical version a pharmacy can simply dispense. The only lawful pathway has historically run through compounding — a 503A pharmacy preparing it from a bulk substance under a valid prescription. And that pathway is exactly what’s in flux.

Here’s the sequence that matters. In late 2023, the FDA placed CJC-1295 (along with around 18 other peptides) on its Category 2 list — bulk substances flagged as presenting potential safety risks, effectively barred from routine compounding. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly signaled that many of those peptides would move back toward compounding eligibility. The companies that had nominated the peptides withdrew their nominations, and the substances came off Category 2 around late April 2026, with the FDA’s Pharmacy Compounding Advisory Committee (PCAC) scheduled to formally review them on July 23–24, 2026.

The trap is assuming “off Category 2” means “legal to compound.” It doesn’t. Coming off the restricted list and being placed on the permitted (Category 1) list are two separate actions. As of June 2026, CJC-1295 is in the gap between them — not formally prohibited, not formally cleared. Some industry and testing sources go further and continue to describe CJC-1295 as a developmental drug that remains restricted, partly because the FDA’s own documentation has cited nonclinical safety concerns specific to it. That disagreement among sources is itself the signal: this is unsettled, and a careful provider or pharmacy will treat it as such.

For a deeper walkthrough of the categories and the timeline, see the 2026 FDA peptide reclassification and compounded peptides: 503A vs 503B explained.

Who can prescribe CJC-1295

Where CJC-1295 can be prescribed at all, the prescriber has to be a licensed clinician acting within their scope of practice and state rules. That typically means a physician (MD or DO), and in many states a nurse practitioner (NP) or physician assistant (PA) with prescribing authority. CJC-1295 is not a controlled substance and carries no DEA scheduling, so there’s no special controlled-substance registration involved — but that does not make it casual. A responsible prescriber is putting their license behind an unapproved peptide, and the more carefully they evaluate you, the more seriously they’re taking that.

A provider willing to write the script without any evaluation, labs, or follow-up plan is a red flag, not a convenience. The same goes for “clinics” whose entire model is rubber-stamping requests. Because CJC-1295’s compounding status is in question, a conscientious provider may also decline outright or steer you toward an FDA-approved alternative in the same therapeutic area — for growth-hormone-axis support, tesamorelin is the approved comparator clinicians often reference.

Telehealth vs in-person: eligibility and how it works

Telehealth is a legitimate route for non-controlled prescriptions, and CJC-1295 is non-controlled. The constraints are about licensure and the provider-patient relationship, not the DEA. In practice a telehealth provider must be licensed in the state where you are located, must establish a valid clinical relationship (an actual evaluation, not a checkout form), and must have a compounding pharmacy partner that can lawfully prepare what’s prescribed.

That last point is where CJC-1295 telehealth runs into the wall described above. Many telehealth platforms that previously offered CJC-1295 paused it when it went onto Category 2, and reinstating it depends on the compounding question being resolved. An in-person clinic faces the same pharmacy-side limitation; being physically in the room doesn’t create a compounding pathway that doesn’t otherwise exist. So the choice between telehealth and in-person is mostly about evaluation quality and monitoring, not about unlocking access. For how to evaluate either kind of provider, see how to choose a peptide clinic or telehealth provider.

What the prescription process actually involves

When CJC-1295 is lawfully available and a provider agrees it’s appropriate, the process looks broadly like this:

1. Intake and history. You share goals, medical history, medications, and any relevant conditions. Growth-hormone-axis peptides are generally avoided in people with active or prior cancer, and your provider should screen for that.
2. Baseline labs. Providers commonly check IGF-1 against age-adjusted reference ranges as the main candidacy marker, alongside fasting glucose, HbA1c, and a comprehensive metabolic panel to establish a safety baseline. GH secretagogues can affect glucose handling, so that baseline matters.
3. Evaluation and decision. The provider weighs whether there’s a defensible reason to use an unapproved peptide versus an approved alternative, and confirms a pharmacy can lawfully fill it.
4. The prescription itself. It must specify which form — see the DAC section below — and the intended preparation, sent to a compounding pharmacy rather than a retail one.
5. Monitoring and follow-up. Repeat labs and check-ins, because the whole point of clinical oversight is catching problems early.

Notice what this page does not give you: numbers. Specific amounts, schedules, and protocols are a clinical decision made by the prescriber for you individually — not something to copy from a website. Anyone publishing “the” CJC-1295 protocol is skipping the part where a real evaluation happens.

DAC vs no-DAC: why your prescription has to specify

CJC-1295 is really two related compounds, and conflating them is one of the most common — and riskiest — mistakes.

• CJC-1295 with DAC is the long-acting form. A Drug Affinity Complex binds it reversibly to albumin, dramatically extending its half-life, which is why it’s associated with infrequent (roughly weekly) administration and a sustained, elevated baseline of growth-hormone signaling.
• CJC-1295 without DAC, usually called modified GRF 1-29 (or “Mod GRF 1-29”), is short-acting, cleared within roughly an hour, and produces brief pulses that more closely mimic the body’s natural rhythm. It’s the form most often meant in the popular “CJC-1295 + ipamorelin” pairing.

They share a core sequence but behave like different drugs. A prescription that just says “CJC-1295” is ambiguous, and ambiguity at a compounding pharmacy is exactly where errors happen. This is also a reason the human safety picture is hard to generalize: the sustained signaling of the DAC form is a different risk profile from the pulsatile no-DAC form, and the evidence base for both is thin. For the underlying comparison, CJC-1295 vs ipamorelin and what is CJC-1295? go deeper.

State-by-state variation

Two layers of state law shape access. The first is who may prescribe: NP and PA prescribing authority and independence vary widely by state, so the same request might go to a physician in one state and an NP in another. The second is how each state board and its pharmacy regulators interpret compounding of a substance in CJC-1295’s ambiguous status. Boards have leeway in how cautious they are about unapproved peptides, and some compounding pharmacies will simply decline anything not clearly on the permitted list regardless of what a provider writes. The result is that “can I get this prescribed and filled?” can have different answers in different states even at the same point in time.

Honest cautions before you pursue a prescription

A few things worth being clear-eyed about:

• The evidence is early. CJC-1295’s human data is limited to early-phase pharmacokinetic work; there are no completed Phase 2 or Phase 3 trials supporting it for the wellness, anti-aging, or body-composition uses it’s marketed for. The original development program was discontinued without registration.
• The FDA has flagged it specifically. Agency documentation has referenced adverse nonclinical findings for CJC-1295. That’s part of why it sits in a more cautious position than some peptides it’s lumped in with, and why it may not move cleanly to Category 1.
• “Research use only” vials are not a prescription. Products sold online as RUO are not made to pharmacy standards, are not a lawful patient route, and have repeatedly been found in independent testing to be mislabeled, underdosed, or contaminated. A real prescription exists precisely to avoid that.
• It’s banned in sport. Under the 2026 WADA Prohibited List, CJC-1295 is prohibited both in and out of competition (class S2). Competitive athletes should treat any use as a doping violation.
• A prescription is not a guarantee of access. Until the compounding question resolves, you may go through an evaluation, get a willing provider, and still find no pharmacy can lawfully fill it.

If your underlying goal is growth-hormone-axis support, it’s worth raising approved options with a provider rather than fixating on a peptide that’s currently this hard to obtain lawfully. And if you do pursue CJC-1295, the value of doing it through a real provider — instead of a website — is the evaluation, the labs, and the person whose license depends on getting it right.

For the broader picture of legal routes and where this fits, see how to get CJC-1295 in the US, are peptides legal in the US?, and how to get peptides prescribed in the US.